IS7287A - Pýrimídín efnasambönd - Google Patents

Pýrimídín efnasambönd

Info

Publication number
IS7287A
IS7287A IS7287A IS7287A IS7287A IS 7287 A IS7287 A IS 7287A IS 7287 A IS7287 A IS 7287A IS 7287 A IS7287 A IS 7287A IS 7287 A IS7287 A IS 7287A
Authority
IS
Iceland
Prior art keywords
pyrimidine compounds
pyrimidine
compounds
Prior art date
Application number
IS7287A
Other languages
English (en)
Inventor
Ono Mitsunori
Sun Lijun
Przewloka Teresa
Zhang Shijie
Kostik Elena
Ying Weiwen
Wada Yumiko
Koya Keizo
Wu Yaming
Zhou Dan
Tatsuta Noriaki
Original Assignee
Synta Pharmaceuticals, Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/000,742 external-priority patent/US6693097B2/en
Application filed by Synta Pharmaceuticals, Corp. filed Critical Synta Pharmaceuticals, Corp.
Publication of IS7287A publication Critical patent/IS7287A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
IS7287A 2001-11-30 2004-05-26 Pýrimídín efnasambönd IS7287A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/000,742 US6693097B2 (en) 2001-11-30 2001-11-30 Pyrimidine compounds
US10/192,347 US6660733B2 (en) 2001-11-30 2002-07-10 2,4,6-trisubstituted-pyrimidine compounds
PCT/US2002/038161 WO2003047516A2 (en) 2001-11-30 2002-11-27 Pyrimidine compounds

Publications (1)

Publication Number Publication Date
IS7287A true IS7287A (is) 2004-05-26

Family

ID=26668093

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7287A IS7287A (is) 2001-11-30 2004-05-26 Pýrimídín efnasambönd

Country Status (16)

Country Link
US (2) US6958332B2 (is)
EP (1) EP1458687B1 (is)
JP (1) JP2005519034A (is)
KR (1) KR100950122B1 (is)
CN (1) CN100349876C (is)
AU (1) AU2002357033B2 (is)
BR (1) BR0214809A (is)
CA (1) CA2468349A1 (is)
IL (1) IL162189A0 (is)
IS (1) IS7287A (is)
MX (1) MXPA04005181A (is)
NO (1) NO328144B1 (is)
NZ (1) NZ533437A (is)
RU (1) RU2320658C2 (is)
TW (1) TWI256953B (is)
WO (1) WO2003047516A2 (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458687B1 (en) * 2001-11-30 2012-01-11 Synta Pharmaceuticals Corporation Pyrimidine compounds as interleukin-12 (il-12) inhibitors
US6693097B2 (en) * 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
EP1556140A4 (en) * 2002-10-15 2006-04-19 Synta Pharmaceuticals Corp NEW COMPOUNDS
JP2007510745A (ja) * 2003-11-10 2007-04-26 シンタ ファーマシューティカルズ コーポレーション 縮合複素環式化合物
JP2007514414A (ja) * 2003-11-10 2007-06-07 シンタ ファーマシューティカルズ コーポレーション c−Rel依存性サイトカイン産生を調節する組成物及び方法
WO2005046604A2 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Heteroaryl-hydrazone compounds
WO2005046603A2 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
AU2005244745B2 (en) * 2004-04-13 2012-05-03 Synta Pharmaceuticals Corp. Disalt inhibitors of IL-12 production
AU2005262322B2 (en) * 2004-07-01 2012-07-26 Synta Pharmaceuticals Corp. 2-substituted heteroaryl compounds
EP1789413A1 (en) 2004-09-13 2007-05-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7919487B2 (en) * 2004-11-10 2011-04-05 Synta Pharmaceuticals Corporation Heteroaryl compounds
US7923557B2 (en) * 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
TW200628159A (en) * 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
US7851466B2 (en) 2004-11-19 2010-12-14 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
WO2006128172A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
TW200804307A (en) * 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
CA2631291A1 (en) * 2005-12-08 2007-06-14 Laboratoires Serono S.A. Antiproliferative pyrimidyl, fused pyrimidyl and pyridyl hydrazones
WO2008110891A2 (en) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
WO2009100406A2 (en) * 2008-02-07 2009-08-13 Synta Pharmaceuticals Corp. Topical formulations for the treatment of psoriasis
PT2254869T (pt) 2008-03-07 2017-07-18 Acraf Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40
AU2009221087B2 (en) 2008-03-07 2013-12-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
JP5578490B2 (ja) 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
EP2518072A4 (en) * 2009-12-24 2014-06-04 Ajinomoto Kk IMIDAZOPYRIDAZINE COMPOUNDS
NZ606660A (en) 2010-07-20 2014-11-28 Vestaron Corp Insecticidal triazines and pyrimidines
CN105963300B (zh) * 2015-03-13 2019-06-11 中国人民解放军军事医学科学院放射与辐射医学研究所 PIKfyve抑制剂抗辐射损伤的用途
CN106279041A (zh) * 2016-08-16 2017-01-04 四川思睿博生物科技有限公司 苯基嘧啶衍生物及其制备方法和用途
BR112020016256A2 (pt) 2018-02-21 2020-12-15 AI Therapeutics, Inc. Terapia de combinação com apilimod e agentes gluta-matérgicos
WO2023118896A1 (en) 2021-12-23 2023-06-29 Subintro Limited Novel antiviral compositions comprising oleic acid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6830751B1 (en) * 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
RU2260592C9 (ru) * 1999-04-15 2017-04-07 Бристол-Маерс Сквибб Ко. Циклические ингибиторы протеинтирозинкиназ
US6384032B1 (en) * 1999-06-17 2002-05-07 Shionogi Bioresearch Corp. Inhibitors of IL-12 production
WO2001047921A1 (en) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
US6525051B2 (en) * 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
US6680315B2 (en) * 2000-06-15 2004-01-20 Synta Pharmaceuticals Corp. Triazine compounds
US6693097B2 (en) * 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
EP1458687B1 (en) * 2001-11-30 2012-01-11 Synta Pharmaceuticals Corporation Pyrimidine compounds as interleukin-12 (il-12) inhibitors
WO2005046604A2 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Heteroaryl-hydrazone compounds

Also Published As

Publication number Publication date
NZ533437A (en) 2007-05-31
BR0214809A (pt) 2004-09-14
IL162189A0 (en) 2005-11-20
RU2320658C2 (ru) 2008-03-27
RU2004119853A (ru) 2006-01-10
WO2003047516A3 (en) 2003-07-31
NO328144B1 (no) 2009-12-14
AU2002357033B2 (en) 2009-05-07
US20040053937A1 (en) 2004-03-18
US7470681B2 (en) 2008-12-30
EP1458687A2 (en) 2004-09-22
CN100349876C (zh) 2007-11-21
KR100950122B1 (ko) 2010-03-30
US20060030560A1 (en) 2006-02-09
WO2003047516A2 (en) 2003-06-12
AU2002357033A1 (en) 2003-06-17
NO20042742L (no) 2004-08-24
CA2468349A1 (en) 2003-06-12
EP1458687A4 (en) 2005-03-23
TW200400190A (en) 2004-01-01
MXPA04005181A (es) 2005-06-17
CN1599726A (zh) 2005-03-23
EP1458687B1 (en) 2012-01-11
TWI256953B (en) 2006-06-21
US6958332B2 (en) 2005-10-25
KR20050058257A (ko) 2005-06-16
JP2005519034A (ja) 2005-06-30

Similar Documents

Publication Publication Date Title
CY2015035I2 (el) Ενωσεις πυριμιδινης
NO20024127D0 (no) Pyrimidin-forbindelser
IS7287A (is) Pýrimídín efnasambönd
DK1419152T3 (da) HIV-hæmmende pyrimidin-derivater
IS6971A (is) Ný efnasambönd
DK1303496T3 (da) Pyrimidinderivater
ATE402148T1 (de) Substituierte pyridinylamine
IS6868A (is) Ný pýrimidínefnasambönd
DE50206892D1 (de) Substituierte imidazotriazinone
NO20032291D0 (no) Pyrimidinderivater
DE50213651D1 (de) Substituierte 4-aminocyclohexanole
DE60216967D1 (de) Substituierte cyclohexanderivate
SE0100629D0 (sv) New compounds
SE0103461D0 (sv) New compounds
SE0104342D0 (sv) New compounds
SE0104366D0 (sv) New compounds
SE0103437D0 (sv) New compounds
SE0102386D0 (sv) New compounds
SE0102056D0 (sv) New Compounds
SE0101958D0 (sv) New compounds
SE0101660D0 (sv) New compounds
SE0101659D0 (sv) New compounds
SE0100272D0 (sv) New compounds
SE0100641D0 (sv) Novel compounds
SE0102156D0 (sv) Novel compounds